This study is not the major mover. It’s the Illucix for prostate cancer that is more important. 24/9 is when we will hear if US FDA approves its use. Then UK/Europe, Canada and Australia come next.
Ann: Telix Supporting Amgen PSMA-Targeting Therapy Trial, page-8
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.48 |
Change
0.300(1.65%) |
Mkt cap ! $6.184B | |||
| Open | High | Low | Value | Volume |
| $18.10 | $18.48 | $17.97 | $12.51M | 683.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1888 | $18.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.49 | 3946 | 4 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| TLX (ASX) Chart |